Brief: Active Biotech Study Confirms Tasquinimod Has Anti-Myeloma Activity
23/05/2025 07:35
May 23 (Reuters) - Active Biotech AB publ ACTI.ST: ACTIVE BIOTECH REPORTS STUDY RESULTS WITH TASQUINIMOD IN HEAVILY PRE-TREATED PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA RESULTS CONFIRM THAT TASQUINIMOD HAS ANTI-MYELOMA ACTIVITY AND IS WELL TOLERATED IN PATIENTS PREVIOUSLY REFRACTORY TO IMID/PI COMBINATION THERAPY. Source text: ID:nMFN8xpbm0 Further company coverage: ACTI.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Active Biotech AB publ
See all newsBrief: Active Biotech Says Japan Grants Patent For Laquinimod Ophthalmic Formulation
Brief: Active Biotech Reports Q2 Operating Profit Of SEK -10.2 Mln
Brief: Active Biotech Expands U.S. Collaboration
Brief: Active Biotech Gets Approval To Resume Enrolment In Hovon 172 MF Study
Brief: Active Biotech Q1 Loss After Tax At SEK 8.4 Million